PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Lung Cancer10.1016/s0169-5002(97)83966-9199718154VP-16 plus ifosfamide plus cisplatin (VIP) in small cell lung cancerAlan Sandlerhttps://api.elsevier.com/content/article/PII:S0169500297839669?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500297839669?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(97)89649-319971870266 A phase II study of VP-16 plus ifosfamide plus cisplatin (VIP) plus concurrent radiation therapy (XRT) for previously untreated limited small cell lung cancer (SCLC): A Hoosier Oncology Group (HOG) trialA.B. Sandler, R. Ansari, W. Fisher, R. Gonin, R. Levy, L.H. Einhornhttps://api.elsevier.com/content/article/PII:S0169500297896493?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500297896493?httpAccept=text/plain
Lung Cancer10.1016/0169-5002(94)91709-4199410S337Concurrent platinum (CDDP)-etoposide (VP-16) chemotherapy plus thoracic radiotherapy (TRT) for limited stage small cell lung cancer (SCLC)https://api.elsevier.com/content/article/PII:0169500294917094?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:0169500294917094?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(97)82853-x1997162-3279A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinbiastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16)https://api.elsevier.com/content/article/PII:S016950029782853X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S016950029782853X?httpAccept=text/plain
Lung Cancer10.1016/0169-5002(91)91939-919917158Concurrent cisplatin(CDDP)-etoposide(VP) chemotherapy plus Thoracic Radiotherapy(TRT) for stageIII Small Cell Lung Cancer(SCLC): A Japanese Lung Cancer Chemotherapy Group (JLCCG) studyhttps://api.elsevier.com/content/article/PII:0169500291919399?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:0169500291919399?httpAccept=text/plain
Lung Cancer10.1016/0169-5002(91)91883-d19917142VP-16, Ifosfamide and cisplatin (VIP) for extensive Small Cell Lung Cancer (SCLC)https://api.elsevier.com/content/article/PII:016950029191883D?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:016950029191883D?httpAccept=text/plain
Lung Cancer10.1016/0169-5002(95)96459-91995121-2155VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancerhttps://api.elsevier.com/content/article/PII:0169500295964599?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:0169500295964599?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(01)00429-92002353293-297Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II studyNasser Hanna, Rafat Ansari, William Fisher, Jianzhao Shen, Sin-Ho Jung, Alan Sandlerhttps://api.elsevier.com/content/article/PII:S0169500201004299?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500201004299?httpAccept=text/plain
Lung Cancer10.1016/0169-5002(94)92150-4199411242A phase III study of VP16 plus cisplatin (VP) alone or with ifosfamide (VIP) in previously untreated patients (pts) with extensive small cell carcinoma of the lung (SCLC): A hoosier oncology group trialhttps://api.elsevier.com/content/article/PII:0169500294921504?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:0169500294921504?httpAccept=text/plain
Lung Cancer10.1016/0169-5002(91)91746-x19917107Phase III trial of cisplatin, vinblastin (VP) vs cisplatin, vinblastin, ifosfamide (VIP) for non-operable non-small lung cancer (NSCLC)https://api.elsevier.com/content/article/PII:016950029191746X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:016950029191746X?httpAccept=text/plain